PMID- 21804276
OWN - NLM
STAT- MEDLINE
DCOM- 20111209
LR  - 20201209
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Linking)
VI  - 50
IP  - 15
DP  - 2011
TI  - Elevated plasma levels of adropin in heart failure patients.
PG  - 1523-7
AB  - BACKGROUND: Recent studies have suggested that a higher body mass index (BMI) is 
      associated with an improved prognosis in heart failure (HF). Adropin is a 
      recently identified protein that has been implicated in the maintenance of energy 
      homeostasis. In the present study, we investigated plasma adropin levels in 
      patients with HF and evaluated the relationship between the levels and the 
      severity of HF. METHODS AND RESULTS: The study group comprised 56 patients with 
      HF and 20 control subjects, who were divided into 4 subgroups according to New 
      York Heart Association (NYHA) functional classification. Plasma levels of 
      adropin, brain natriuretic peptide (BNP) and cardiac hemodynamics were 
      determined. Plasma adropin levels were significantly increased according to the 
      severity of NYHA class in the patients with HF; control: 6.0 +/- 0.3; NYHA 
      functional Class II: 7.6 +/- 0.4; NYHA functional Class III: 9.8 +/- 0.5; NYHA 
      functional Class IV: 12.4 +/- 0.6 ng/mL (p<0.01). Similarly, plasma BNP levels were 
      significantly increased in accordance with the NYHA class. Plasma adropin levels 
      were correlated positively with BNP (r=0.723, p<0.001), interleukin-6 (IL-6) 
      (r=0.326, p=0.007) and body mass index (BMI) (r=0.295, p=0.014), and negatively 
      with left ventricular ejection fraction (LVEF) (r=-0.710, p<0.001). CONCLUSION: 
      Plasma adropin levels were significantly increased according to the severity of 
      HF, and BNP and BMI had independent impact on the plasma adropin level. These 
      findings suggest that the augmented release of adropin may be involved in the 
      pathogenesis of HF and further study is necessary to explain the precise role of 
      adropin in HF.
FAU - Lian, Wenlin
AU  - Lian W
AD  - Department of Cardiovascular Diseases, Changhai Hospital, Second Military Medical 
      University, China.
FAU - Gu, Xiaosong
AU  - Gu X
FAU - Qin, Yongwen
AU  - Qin Y
FAU - Zheng, Xing
AU  - Zheng X
LA  - eng
PT  - Journal Article
DEP - 20110801
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Blood Proteins)
RN  - 0 (Enho protein, human)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Peptides)
RN  - 0 (Proteins)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Blood Proteins/*metabolism
MH  - Case-Control Studies
MH  - Female
MH  - Heart Failure/*blood/classification/diagnosis
MH  - Humans
MH  - Intercellular Signaling Peptides and Proteins
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptides
MH  - Proteins/*metabolism
MH  - ROC Curve
MH  - Regression Analysis
EDAT- 2011/08/02 06:00
MHDA- 2011/12/14 06:00
CRDT- 2011/08/02 06:00
PHST- 2011/08/02 06:00 [entrez]
PHST- 2011/08/02 06:00 [pubmed]
PHST- 2011/12/14 06:00 [medline]
AID - JST.JSTAGE/internalmedicine/50.5163 [pii]
AID - 10.2169/internalmedicine.50.5163 [doi]
PST - ppublish
SO  - Intern Med. 2011;50(15):1523-7. doi: 10.2169/internalmedicine.50.5163. Epub 2011 
      Aug 1.